| | | | | | | | |
| | Six Months Ended June 30, | |
(in thousands) | | 2021 | | | 2020 | |
Cash flows from operating activities | | | | | | | | |
Net income (loss) | | $ | 8,960 | | | $ | (3,663 | ) |
Adjustments to reconcile net loss to net cash from operating activities: | | | | | | | | |
Depreciation and amortization | | | 236 | | | | 204 | |
Stock-based compensation | | | 4,172 | | | | 18 | |
Amortization of debt issuance costs | | | 14 | | | | 130 | |
Accretion of debt discount | | | 2,211 | | | | 40 | |
Change in fair value of derivative liability | | | 1,426 | | | | (15 | ) |
Change in fair value of warrants liability | | | 20,844 | | | | 105 | |
Change in fair value of earnout liability | | | (45,497 | ) | | | — | |
Changes in operating assets and liabilities: | | | | | | | | |
Other receivables | | | (112 | ) | | | 960 | |
Grants receivable | | | (17 | ) | | | 4 | |
Prepaid expenses and other current assets | | | (29 | ) | | | 86 | |
Accounts payable | | | (1,880 | ) | | | (536 | ) |
Accrued expenses | | | 2,899 | | | | 396 | |
Related party payable | | | 98 | | | | — | |
| | | | | | | | |
Net cash used in operating activities | | | (6,675 | ) | | | (2,271 | ) |
| | | | | | | | |
Cash flows from investing activities | | | | | | | | |
Purchases of property, plant, and equipment, net of grants | | | (2,703 | ) | | | (1,267 | ) |
| | | | | | | | |
Net cash used in investing activities | | | (2,703 | ) | | | (1,267 | ) |
| | | | | | | | |
Cash flows from financing activities | | | | | | | | |
Proceeds from notes payable, net of debt issuance costs | | | 11,707 | | | | 906 | |
Payment of short-term debt | | | (906 | ) | | | — | |
Proceeds from Canadian Government Research and Development Program | | | 173 | | | | 1,055 | |
Issuance of common stock | | | 55 | | | | 1 | |
Business combination, net of issuance costs paid | | | 467,530 | | | | — | |
| | | | | | | | |
Net cash provided by financing activities | | | 478,559 | | | | 1,962 | |
| | | | | | | | |
Effects of foreign exchange rate changes on the balance of cash and cash equivalents, and restricted cash held in foreign currencies | | | (178 | ) | | | 184 | |
| | | | | | | | |
Net increase (decrease) in cash and cash equivalents, and restricted cash | | | 469,003 | | | | (1,392 | ) |
Cash and cash equivalents, and restricted cash, beginning of the period | | | 1,874 | | | | 3,612 | |
| | | | | | | | |
Cash and cash equivalents, and restricted cash, end of the period | | $ | 470,877 | | | $ | 2,220 | |
| | | | | | | | |
Supplemental disclosure of cash flow information | | | | | | | | |
Conversion of stockholder convertible notes payable to common stock | | $ | 20,493 | | | $ | — | |
| | | | | | | | |
Reclassification of redeemable convertible preferred stock warrants to common stock | | $ | 54,267 | | | $ | — | |
| | | | | | | | |
Reclassification of contingently issued equity to liability | | $ | 209,380 | | | $ | — | |
| | | | | | | | |
Net assets assumed from business combination | | $ | 83,330 | | | $ | — | |
| | | | | | | | |
Debt discount related to derivative liability | | $ | 2,196 | | | $ | — | |
| | | | | | | | |
Business combination transaction costs, accrued but not paid | | $ | 748 | | | $ | — | |
| | | | | | | | |